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Introduction
Although intra-articular injection of corticosteroids (IAIC) has been a commonly used procedure among rheumatologists for over half a century, 1 few studies have been conducted to demonstrate its benefits in accordance to scientific methodology.
Rheumatoid arthritis (RA) is the rheumatic condition that most severely affects the joints. Pannus, the hypertrophic and hyperplasic synovial membrane formed, is an aggressive tissue that damages articular and periarticular structures, whether through the release of metaloproteinases or its mechanical invasion of the surrounding joint space. [2] [3] [4] Even though RA treatment has evolved in recent decades with the advent of immunobiological therapy allied with disease-modifying antirheumatic drugs (DMARDs), 5 patients with mono or oligoarticular synovitis may persist. In these cases, IAIC can be a useful therapeutic tool.
It is known that triamcinolone hexacetonide (TH) is the drug of choice for intra-articular treatment of RA, given its synovial atrophying properties and slow absorption from the injection site. [6] [7] [8] [9] [10] [11] [12] [13] On the other hand, if injected outside of the joint, it can cause serious adverse local effects. 14 Though some concepts concerning IAIC have been established, few studies have been conducted to evaluate response predictors in adult RA patients. 15 In addition, to the best of our knowledge, none of them evaluated TH IAIC response predictors in patients with established RA.
The aim of this study was to identify variables (clinical, demographic and related to injection) that serve as the best predictors of response to TH IAIC over short term (4 weeks) and long term (24 weeks) in patients with established RA.
Materials and methods
A prospective non-controlled study was conducted on a cohort of patients with established RA receiving treatment at the Interventional Rheumatology Unit at Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Patients were classified according to American College of Rheumatology -ACR 16 criteria, and had been referred for IAIC (mono, pauci or polyarticular).
Inclusion criteria were: age between 18 and 65; functional class II or III; 17 stable DMARD for the last 3 months; stable oral corticosteroid for the last month; indication for IAIC injection (persistent synovitis with swelling and articular pain) and must have signed the informed consent form.
Exclusion criteria were: IAIC in any joint within the last 6 months; any symptoms of systemic or articular infection; any form of clotting disturbance; diagnosis of diabetes mellitus or systemic arterial hypertension; known allergy to contrasts or radioisotopes, and suspicion of pregnancy.
Most of the joints injections were not guided. Fluoroscopy and ultrasound were used for guided injections, as needed. Image-guided IAIC was recommended in cases of difficult blind access or where the use of radioisotopes was recommended.
Intervention
Patients received IAIC in one or more of the following joints: shoulder (glenohumeral), elbow, wrist, metacarpophalangeal (MCP), knee and ankle. The procedure was carried only at the baseline by the same rheumatologist, with over ten years of experience in interventional rheumatology (RNV Furtado). The IAIC was mono, pauci (up to three infiltrations at once) or polyarticular (4 to 8 simultaneous IAIC), depending on the number of joints indicating pain and swelling.
The only corticosteroid used was triamcinolone hexacetonide (20 mg/mL). Depending on the size of the joint space, dose of corticosteroid was considered low (1), medium (2) and high (3) . The dose of TH used for each joint studied were: shoulder, 80 mg (3); elbow, 40 mg (2) or 60 mg (3); wrist, 30 mg (2) or 40 mg (3); metacarpophalangeal, 10 mg (2) or 20 mg (3); knee, 40 mg (1), 60 mg (2) or 80 mg (3); and ankle, 40 mg (2) or 60 mg (3) .
Patients received the IAIC procedure in dorsal decumbency after the injection site had been cleansed with topical povidine. Only sterile needles and syringes were used. Xylocaine chloride 2% without vasoconstrictor was used for anesthetic purpose. TH was only administered once the needle had been corrected positioned inside the joint space.
In patients submitted to knee IAIC with radioisotopes, all the safety norms for radioactive material handling were followed. The dose applied was 5 mCi Yttrium-90 plus 40 mg of TH, or 15 mCi Samarium-153 hydroxyapatite plus 40 mg of TH, depending on availability. These drugs were used only in cases of refractory synovitis only in the knee.
All patients were warned to rest for a period of 48 hours after injection, only allowed to move around to meet their physiological needs. An orthotic immobilizer was used in case of IAI with radioisotopes.
Assessment
"Blinded" examination at T0 (baseline), T1, T4, T12, and T24 weeks post-injection were performed. Outcome measures included: visual analogue scale (0-10 cm) for joint pain at rest (VASr); visual analogue scale (0-10 cm) for joint pain in movement (VASmv) and visual analogue scale for swollen joints (VASs).
IAIC response was assessed in relation to the injected joint (rather than the patient as a whole) and was measured as percentage (%) of improvement on the VASr, VASmv and VASs scales for each joint at times T1, T4, T12 and T24. Improvement between 50% and 70% was considered moderate, and over 70% was considered significant. The association between improvement percentages for VASr, VASmv and VASs was made in isolation (50%-70% and > 70%) and concomitantly (improvement > 50% in all three VAS at once) and multiple baseline variables were factored in.
Baseline variables considered under this analysis were: demographic (gender, age and skin color -white or nonwhite); related to disease (duration, functional class II or III, presence of rheumatoid factor, DMARDS in use, use of oral corticosteroid and presence of extra-articular disease) and related to injection (joint injected, previous IAI, number of joints injected, TH dose, total TH dose per patient, image guided IAI and use of radioisotope or contrast agent).
Statistical analysis
The continuous variables were described in mean and standard deviation (SD), and the categorical variables in frequencies and percentages.
Comparison between continuous and categorical baseline variables was made using Kruskal-Wallis univariate analysis, while comparison between categorical baseline variables was performed using chi-square or Fisher's exact tests.
Only those joints showing improvement percentages higher than 50% concomitantly for all three VAS (VASr, VASmv and VASs) were subjected to multivariate logistic regression analysis, with the chance of improvement measured in Odds Ratio (OR) (IC 95%).
Significant p value was set at 5%.
Ethics
Written informed consent was obtained from all subjects, and the Ethics Committee of the university approved the study. 
Results
We studied 289 patients with RA with a mean age of 47.6 years (SD ± 10.81) and mean disease duration of 11.2 years (SD ± 8.23), 48.5% white and women-to-men ratio of 9:1, VAS for global pain 6.52 (±1.73). Monoarticular injection occurred in 175 patients (60.55%); pauciarticular injection in 68 patients (23.53%), and polyarticular injection in 46 patients (15.92%). Six hundred and thirty-five (635) joints were injected and prospectively studied through T4; 403 through T12, and 313 through T24. Table 1 presents the demographic data and data related to disease and related to injection for the sample patients. Baseline variables that did not correlate statistically with VAS improvement at any of the assessment times were: image-guided IAIC, use of radioisotopes and use of contrast in IAIC.
Univariate analysis (Kruskal-Wallis) between VAS improvements and baseline variables revealed various IAIC response predictors.
In terms of moderate improvement (50-70%) on post-IAIC, the statistically associated baseline variables were (p < 0.05): VASmv, at T4 -lower use of NSAIDs at baseline; at T24 -knee IAIC; VASr, at T4 -higher dose of MTX; at T12 -knee IAIC, higher total TH dose per patient; at T24 -wrist IAIC, longer disease duration, higher use of NSAIDs at baseline; VASs, at T12knee IAIC, medium dose of TH per IAIC, male gender ( Table 2) .
The best outcome predictors for significant improvement post-IAIC (> 70%) were (p < 0.05): VASmv, at T4 -elbow and knee IAIC, longer disease duration; at T12 -MCP IAIC, higher dose of TH per IAIC, polyarticular injection, higher total dose of TH per patient, lower mean age, functional class II, use of chloroquine, no use of leflunomide; no previous IAIC; at T24 -MCP IAIC, higher TH dose per IAIC, higher total TH dose per patient, polyarticular injection, lower mean age, non-white skin color, functional class II, more extra-articular disease, no use of leflunomide; VASr, at T4 -wrist and knee IAIC, higher TH dose per IAIC, use of methotrexate; at T12 -MCP IAIC, higher TH dose per IAIC, higher TH dose per patient, non-white skin color, functional class II, no use of leflunomide; at T24 -MCP (Table 2) . Multivariate logistic regression also showed that some of the variables presented at baseline were considered IAIC response predictors (Table 3 ).
In the short term (T4), the only variables that were predictors of best IAIC response were: "male gender" and "non-white skin color". On the other hand, "wrist, MCP and ankle IAIC", "do polyarticular injection", "be using chloroquine" and "higher total dose of TH per patient" were the predictors for the worst IAIC response in the short term.
In the long term (T24), various baseline variables were predictors of the best IAIC response, the most important of which was "do elbow IAIC" (with a 4.4 times higher chance of success), followed by "do MCP IAIC", "do polyarticular injection", "be using MTX" and "higher total dose of TH" per patient ( Table 3 ). The baseline variables associated with the worst long-term IAIC response were: "non-white skin color", "rheumatoid factor positivity", "functional class III", and "be using chloroquine and oral corticosteroid". Multivariate logistic regression did not show any medium-term (T12) improvement predictor.
Only mild and transitory local adverse effects were observed. Post-IAIC inflammatory flare was observed in 37.82% of the patients (related by the patients but not observed by the blinded observer at T1). Skin atrophy, skin hypochromic and articular instability were observed in 1.9%, 15.3% and 2.0% of the patients, respectively.
Discussion
This was a prospective, non-controlled study conducted on a cohort of patients with established RA receiving TH IAIC injection, a description of a great experience of our group. Though known as the most effective corticosteroid for intra-articular use, [6] [7] [8] [10] [11] [12] we are unaware of other similar studies in which TH was used as an IAIC drug.
Our group has already published few studies in which RA patients were submitted to TH IAIC injection. Monoarticular and polyarticular IAIC effectiveness was considered superior to systemic use of corticosteroids; 10,11 ankle was considered the joint with lowest accuracy for blinded IAIC; 6 the use of ultrasound to guide TH injection did not increase its effectiveness in wrists joint, 12 and the use of radioisotopes (Yttrium-90 and Samarium-153-particulate hydroxyapatite) did not improved TH IAIC effectiveness when compared to injection of TH IAIC alone. 7, 8 Uncommon TH doses, as 20 mg for MCP joint or 80 mg for knee joint, were used in our study. The ideal TH doses for IAIC have not been already established, but the most commonly used dosages are 40 mg of TH for large joints and 10-20 mg for small to medium-sized joints. 6, 11, 14, 18, 19 Some authors, however, have used optimized doses of TH somewhat similar to ours, 6, 11, 14 without the occurrence of any significant adverse effects.
In our study, the use of radioisotopes was not related to any articular improvement at any of the evaluation time's post-IAIC. Increased IAIC effectiveness when associated with the use of the Yttrium-90 and Samarium-153 Hydroxyapatite has been questioned by previous studies. 7, 8, 20, 21 Univariate analysis found that baseline variables as "higher TH doses applied via IAIC and per patient", "polyarticular injection" and "be using leflunomide" were associated with the worst IAIC responses. Perhaps a more aggressive TH dose administered via IAIC and a greater number of joints injected are associated with higher post-IAIC articular flare and, therefore, with a clearer perception of short-term aggravation.
On the other hand, the variables "do MCP" and "do elbow" IAIC, "functional class II" and "higher doses of TH per joint and per patient" were repeatedly associated with best IAIC responses, especially over the long term. Some of these variables have already been shown to be best response predictors for IAIC using TH, most notably "do elbows" and "do MCP" IAIC. 6, 11 However, "functional class III", "higher oral dose of corticosteroid" and "higher dose of TH per patient" had not been identified as good IAIC response predictors over the long term. Higher dose of TH correctly introduced into the joint space might prove to be more effective than a lower dose, though this conclusion needs to be confirmed with prospective studies.
Other studies that evaluate IAIC response predictors 15, [22] [23] [24] [25] have been already published, but few of them used TH as the chosen corticosteroid. 22, 24 In the study conducted by Green et al., 15 fifty-one patients, with less than or equal to five joints with synovitis, were treated with methylprednisolone IAIC. Predictors of response were studied being the primary endpoint a complete response at 12 weeks. Twenty-nine patients (57%) had a complete response at 2 weeks. The best predictor of response at 12 and 26 weeks was the complete response at 2 weeks. 15 The present study used TH rather than methylprednisolone; it evaluated a higher number of patients and did not study the relationship between IAIC responses obtained at the first assessment time and those obtained during subsequent evaluation times.
Eder et al. 25 25 Similarly to our study, Eder et al. 25 also studied a greater number of patients and found that the use of MTX was a predictive factor of IAIC response. However, the diseases studied were different, which make it difficult to compare both sets of results.
Hetland et al. 23 evaluated betamethasone IAIC response in 160 patients with early RA. One thousand three hundred and seventy-three joints (ankles, elbows, knees, MCP, metatarsophalangeal, proximal interphalangeal (PIP), shoulders, wrists) were injected (once or repeated injections) during 2 years. All joint areas had good 2-year joint injection survival, longest for PIP joints: 73.7%. A higher MRI synovitis score of MCP joints and anti-CCP-negativity were associated with poorer joint injection survival, whereas IgM-RF and C-reactive protein were not. Like our study, IAIC injection of small hand joint was a good IAIC-response predictor. However, the presence of positive rheumatoid factor was associated with worse IAIC responses at T24 and repeated injections in the same joint space were not performed. The time of onset of RA and the drug injected were important differences between the studies.
According to our multivariate logistic regression analysis, an association with best IAIC response was observed in only seven baseline variables. "Being male" and "non-white skin color" was associated with best IAIC responses over the short term. However, the stronger associations with best IAIC response over the long term (24 weeks) were observed for the variables "do elbow and MCP IAIC", "do polyarticular injection", "be using methotrexate" and "higher total dose of TH per patient". As initially shown by univariate analysis, "do elbow" and "do MCP" IAIC remained the baseline variables predictive of best IAIC response. The benefit of polyarticular injection, which implies the use of a higher total dose of corticosteroid per patient, was proven by previous controlled studies using methylprednisolone and TH. 11, 26 As already suggested by Eder et al., 25 "be taking methotrexate", given its diseasemodifying action on synovitis, favor a positive IAIC response in
